ABSTRACT
BACKGROUND AND PURPOSE: Mild traumatic brain injury (mTBI) has an estimated worldwide incidence of >60 million per year, and long-term persistent postconcussion symptoms (PPCS) are increasingly recognized as being predicted by psychosocial variables. Patients at risk for PPCS may be amenable to closer follow-up to treat modifiable symptoms and prevent chronicity. In this regard, similarities seem to exist with psychosocial risk factors for chronicity in other health-related conditions. However, as opposed to other conditions, no screening instruments exist for mTBI. METHODS: A systematic search of the literature on psychological and psychiatric predictors of long-term symptoms in mTBI was performed by two independent reviewers using PubMed, Embase, and Web of Science. RESULTS: Fifty papers were included in the systematic analysis. Anxiety, depressive symptoms, and emotional distress early after injury predict PPCS burden and functional outcome up to 1 year after injury. In addition, coping styles and preinjury psychiatric disorders and mental health also correlate with PPCS burden and functional outcome. Associations between PPCS and personality and beliefs were reported, but either these effects were small or evidence was limited. CONCLUSIONS: Early psychological and psychiatric factors may negatively interact with recovery potential to increase the risk of chronicity of PPCS burden after mTBI. This opens opportunities for research on screening tools and early intervention in patients at risk.
Subject(s)
Brain Concussion , Mental Disorders , Post-Concussion Syndrome , Humans , Brain Concussion/complications , Brain Concussion/epidemiology , Post-Concussion Syndrome/diagnosis , Post-Concussion Syndrome/etiology , Post-Concussion Syndrome/psychology , Mental Disorders/complications , Risk FactorsSubject(s)
Catatonia/chemically induced , Drug Interactions/physiology , Lorazepam/adverse effects , Stupor/chemically induced , Valproic Acid/adverse effects , Adult , Anti-Anxiety Agents/adverse effects , Anti-Anxiety Agents/urine , Antimanic Agents/adverse effects , Antimanic Agents/urine , Catatonia/diagnosis , Catatonia/urine , Female , Humans , Lorazepam/urine , Psychotic Disorders/drug therapy , Psychotic Disorders/urine , Stupor/diagnosis , Stupor/urine , Valproic Acid/urineABSTRACT
The pace of research and development in neuroscience, neurotechnology, and neurorehabilitation is rapidly accelerating, with the number of publications doubling every 4.2 years. Maintaining this progress requires technological standards and scientific reporting guidelines to provide frameworks for communication and interoperability. The present lack of such neurotechnology standards limits the transparency, repro-ducibility, and meta-analysis of this growing body of literature, posing an ongoing barrier to research, clinical, and commercial objectives. Continued neurotechnological innovation requires the development of some minimal standards to promote integration between this broad spectrum of technologies and therapies. To preserve design freedom and accelerate the translation of research into safe and effective technologies with maximal user benefit, such standards must be collaboratively co-developed by the full range of neuroscience and neurotechnology stakeholders. This paper summarizes the preliminary recommendations of IEEE P2794 Standards Working Group, developing a Reporting Standard for in-vivo Neural Interface Research (RSNIR).